Back to top
more

Surgery Partners (SGRY)

(Delayed Data from NSDQ)

$28.75 USD

28.75
434,028

-0.05 (-0.17%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $28.75 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Abbott's (ABT) Q4 Earnings Match Estimates, Margins Rise

by Zacks Equity Research

Abbott (ABT) delivers better-than-expected revenues and in-line earnings for the fourth quarter of 2023.

Will the Individual MA Unit Aid Humana's (HUM) Q4 Earnings?

by Zacks Equity Research

Humana's (HUM) Q4 results are likely to gain from growing premiums and an expanding customer base within its individual Medicare Advantage and Medicaid units, partly offset by higher marketing spend.

Compared to Estimates, Surgery Partners (SGRY) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Surgery Partners (SGRY) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Surgery Partners (SGRY) Soars 9.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Surgery Partners (SGRY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Surgery Partners (SGRY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Surgery Partners (SGRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ensign Group (ENSG) Pursues Facility Buyouts in South Carolina

by Zacks Equity Research

Ensign Group (ENSG) acquires two skilled nursing facilities in South Carolina to offer enhanced healthcare services to the state's residents.

Select Medical (SEM) Up 18% Year to Date: More Room to Run?

by Zacks Equity Research

Select Medical (SEM) is well-poised for growth on the back of a credible healthcare facility portfolio built through buyouts and JVs coupled with strong cash-generating abilities.

Zacks Industry Outlook Highlights Medpace, HealthEquity and Surgery Partners

by Zacks Equity Research

Medpace, HealthEquity and Surgery Partners are part of the Zacks Industry Outlook article.

Urmimala Biswas headshot

3 Medical Services Stocks Countering Industry-Wide Headwinds

by Urmimala Biswas

The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, HQY and SGRY are set to gain the most. However, staffing shortages may disrupt the trend.

Down -22.17% in 4 Weeks, Here's Why Surgery Partners (SGRY) Looks Ripe for a Turnaround

by Zacks Equity Research

Surgery Partners (SGRY) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Molina Healthcare (MOH) Wins Medicaid Deal From New Mexico HSD

by Zacks Equity Research

Molina Healthcare (MOH) receives a contract from the New Mexico HSD, subsequent to which it can effectively serve the statewide Medicaid members.

New Strong Buy Stocks for August 15th

by Zacks Equity Research

SGRY, DFH, CDRE, DHI and KB have been added to the Zacks Rank #1 (Strong Buy) List on August 15, 2023.

Compared to Estimates, Surgery Partners (SGRY) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Surgery Partners (SGRY) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Surgery Partners (SGRY) Surpasses Q2 Earnings Estimates

by Zacks Equity Research

Surgery Partners (SGRY) delivered earnings and revenue surprises of 300% and 0.05%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Surgery Partners (SGRY): Can Its 5.0% Jump Turn into More Strength?

by Zacks Equity Research

Surgery Partners (SGRY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Surgery Partners (SGRY) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Surgery Partners (SGRY) delivered earnings and revenue surprises of 900% and 3.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Surgery Partners (SGRY) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Surgery Partners (SGRY) delivered earnings and revenue surprises of 28.57% and 2.73%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Apollo Medical Holdings, Inc. (AMEH) Lags Q4 Earnings Estimates

by Zacks Equity Research

Apollo Medical Holdings, Inc. (AMEH) delivered earnings and revenue surprises of -77.78% and 11.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Medpace (MEDP) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Medpace (MEDP) delivered earnings and revenue surprises of 19.10% and 2.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Are Investors Undervaluing AMN Healthcare Services (AMN) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Surgery Partners (SGRY) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Surgery Partners (SGRY) delivered earnings and revenue surprises of -150% and 0.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CareDx (CDNA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

CareDx (CDNA) delivered earnings and revenue surprises of 57.14% and 2.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Surgery Partners (SGRY) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Surgery Partners (SGRY) delivered earnings and revenue surprises of 0% and 1.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Do Options Traders Know Something About Surgery Partners (SGRY) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Surgery Partners (SGRY) stock based on the movements in the options market lately.

Surgery Partners (SGRY) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Surgery Partners (SGRY) delivered earnings and revenue surprises of -80% and 2.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?